Scholarlink

<p>Translocation (14;14)(q11;q32) with <i>immunoglobulin heavy chain</i> (<i>IGH</i>) (14q32) and <i>CCAAT enhancer-binding protein</i> (<i>CEBPE</i>) (14q11) involvement is a rare cytogenetic aberration in B-cell acute lymphoblastic leukemia/lymphoma (B-ALL) associated with a favorable prognosis. This study compares the genetic profile and outcome of a new case with previously reported cases of B-ALL with t(14;14)(q11;q32). In the context of routine diagnostic procedure, a case of B-ALL with t(14;14)(q11;q32) and <i>IGH</i>-<i>CEBPE</i> fusion was identified in a 53-year-old female. The patient achieved complete remission (CR) during induction chemotherapy and remained stable on maintenance therapy for 8&#xa0;months before passing away from infectious complications, without evidence of leukemic disease. The rapid and sustained treatment response supports the concept that t(14;14)(q11;q32) with <i>IGH</i> and <i>CEBPE</i> involvement may represent a novel B-ALL subgroup distinguished by a favorable prognosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A rare case of B-cell acute lymphoblastic leukemia with translocation (14;14)(q11.2;q32) involving IGH and CEBPE with review of the literature

  • 期刊论文

  • 发表日期：

    2025年5月9日

查看全文
  • Christine Sholy,
  • Linnea Banker,
  • Lakshmi R. Chelapareddy,
  • Richard D. Hammer

摘要

Translocation (14;14)(q11;q32) with immunoglobulin heavy chain (IGH) (14q32) and CCAAT enhancer-binding protein (CEBPE) (14q11) involvement is a rare cytogenetic aberration in B-cell acute lymphoblastic leukemia/lymphoma (B-ALL) associated with a favorable prognosis. This study compares the genetic profile and outcome of a new case with previously reported cases of B-ALL with t(14;14)(q11;q32). In the context of routine diagnostic procedure, a case of B-ALL with t(14;14)(q11;q32) and IGH-CEBPE fusion was identified in a 53-year-old female. The patient achieved complete remission (CR) during induction chemotherapy and remained stable on maintenance therapy for 8 months before passing away from infectious complications, without evidence of leukemic disease. The rapid and sustained treatment response supports the concept that t(14;14)(q11;q32) with IGH and CEBPE involvement may represent a novel B-ALL subgroup distinguished by a favorable prognosis.